Response guided therapy in patients with chronic hepatitis C - Yesterday, today and tomorrow

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 463-469

  Ferenci, Peter ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Direct acting antivirals; Hepatitis C; Peginterferon; Response guided therapy; Ribavirin

Indexed keywords

BOCEPREVIR; INTERLEUKIN 28B; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ARTICLE; COMBINATION CHEMOTHERAPY; ETHNICITY; GENOTYPE; HEPATITIS C; HUMAN; NONHUMAN; PREDICTOR VARIABLE; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INDUCTION CHEMOTHERAPY; INTERFERON-ALPHA; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84870427882     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.002     Document Type: Article

References (39)

1. M.W. Fried, M.L. Shiffman, and K.R. Reddy Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection N Engl J Med 347 2002 975 982
2. A. Craxi' EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
3. S.J. Hadziyannis, H. Sette Jr., and T.R. Morgan Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose Ann Intern Med 140 2004 346 355
4. M.P. Manns, J.G. McHutchison, and S.C. Gordon Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial Lancet 358 2001 958 965
5. P. Ferenci, M.W. Fried, and M.L. Shiffman Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin J Hepatol 43 3 2005 425 433
6. S. Zeuzem Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 140 5 2004 370 381
7. D. Ge, J. Fellay, and A.J. Thompson Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance Nature 461 7262 2009 399 401
8. D.L. Thomas, C.L. Thio, and M.P. Martin Genetic variation in IL28B and spontaneous clearance of hepatitis C virus Nature 461 7265 2009 798 801
9. J.J. McCarthy, J.H. Li, and A. Thompson Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin Gastroenterology 138 7 2010 2307 2314
10. A.J. Thompson, A.J. Muir, and M.S. Sulkowski Interleukin-28B polymorphism im-proves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus Gastroenterology 139 2010 120 129
11. A.F. Stättermayer, R. Stauber, and H. Hofer Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C Clin Gastroenterol Hepatol 9 4 2011 344 350
12. S.S. Lee, V.G. Bain, and K. Peltekian Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice Aliment Pharmacol Ther 23 3 2006 397 408
13. P. Marcellin, N. Reau, and P. Ferenci Refined prediction of week 12 response and SVR based on week 4 response in HCV genotype 1 patients treated with peginterferon alfa-2a (40 KD) and ribavirin J Hepatol 56 6 2012 1276 1282
14. G.L. Davis, J.B. Wong, and J.G. McHutchison Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C Hepatology 38 3 2003 645 652
15. Marcellin P, Cheinquer H, Curescu M, et al. High SVR rates in RVR patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology; in press. [Epub ahead of print]
16. D.M. Jensen, T.R. Morgan, and P. Marcellin Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 KD)/ribavirin therapy Hepatology 43 5 2006 954 960
17. V. Di Martino, C. Richou, and J.P. Cervoni Response-guided Peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future Hepatology 54 3 2011 789 800
18. P. Ferenci, H. Laferl, and T.M. Scherzer Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response Gastroenterology 135 2 2008 451 458
19. S. Zeuzem, M. Buti, and P. Ferenci Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia J Hepatol 44 1 2006 97 103
20. P. Ferenci, H. Laferl, and T.M. Scherzer Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response Gastroenterology 138 2010 503 512
21. A. Mangia, N. Minerva, and D. Bacca Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial Hepatology 47 1 2008 43 50
22. M.L. Yu, C.Y. Dai, and J.F. Huang Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial Hepatology 47 6 2008 1884 1893
23. T. Berg, M. von Wagner, and S. Nasser Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin Gastroenterology 130 4 2006 1086 1097
24. B.L. Pearlman, C. Ehleben, and S. Saifee Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders Hepatology 46 6 2007 1688 1694
25. M. Buti, Y. Lurie, and N.G. Zakharova Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response Hepatology 52 4 2010 1201 1207
26. J.M. Sanchez-Tapias, M. Diago, and P. Escartin Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment Gastroenterology 131 2 2006 451 460
27. D.M. Jensen, P. Marcellin, and B. Freilich Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial Ann Intern Med 150 8 2009 528 540
28. F. Poordad, J. McCone Jr., and B.R. Bacon Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
29. I.M. Jacobson, J.G. McHutchison, and G. Dusheiko Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
30. T.W. Chu, R. Kulkarni, and E.J. Gane Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C Gastroenterology 142 2012 790 795
31. Wedemeyer H, Jensen DM, Godofsky E et al. Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents. Hepatology; in press. [Epub ahead of print]
32. T.M. Scherzer, A.F. Stättermayer, and M. Strasser Impact of IL28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with peginterferon alpha-2a (40 KD)/ribavirin Hepatology 54 2011 1518 1526
33. J.-P. Bronowicki, C. Hezode, and L. Bengtsson 100% SVR in IL28B CC patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the PROVE2 trial J Hepatol 56 Suppl. 2 2012 S430 S431
34. Thompson AJ, McHutchison JG. Will IL28B polymorphism remain relevant in the era of direct acting antiviral agents for HCV? Hepatology; 2012, in press. http://dx.doi.org/10.1002/hep. 25792.
35. F. Poordad, J.P. Bronowicki, and S.C. Gordon IL28b polymorphism predicts virological response in patients with chronic hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy J Hepatol 54 2011 S12
36. M.S. Sulkowski, E. Ceasu, and T. Asselah SILEN-C1: sustained virologic response (SVR) and safety of BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype 1 HCV infection J Hepatol 54 Suppl. 1 2011 S27
37. M. Fried, M. Buti, and G.J. Dore TMC435 in combination with peginterferon and ribavirin in treatment-naïve HCV genotype 1 patients: final analysis of the PILLAR phase IIb study Hepatology 54 Suppl. 1 2011 LB5
38. I.M. Jacobson, I. Catlett, and P. Marcellin Telaprevir substantially improves SVR rates across all IL28B genotypes in the ADVANCE trial J Hepatol 54 2011 S1369
39. S. Beinhardt, A.F. Staettermayer, and K. Rutter Treatment of chronic hepatitis C GT 1 patients at an academic center in Europe involved in prospective c controlled trials - Is there a selection bias? Hepatology 55 2012 30 38